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Abstract 
 
Carbonic anhydrases (CAs) are widespread metalloenzymes that catalyze the interconversion of a 
water molecule and carbon dioxide into bicarbonate and hydrogen ions.  In mammals, CAs are involved in 
many vital processes such as regulation of pH and fluid balance and transport of carbon dioxide. However, 
activity of some CA isoforms can also promote several pathologies. 
The enzymatic activity of human CA isoform II (hCA II) is associated with glaucoma. It increases the 
concentration of the bicarbonate ion in the eye, followed by intake of Na+ ions and water flow along the 
gradient, thereby increasing intraocular pressure. Increased intraocular pressure is damaging to the eye 
nerve, which can lead to complete blindness. hCA II inhibitors are used as anti-glaucoma medicaments, able 
to decrease intraocular pressure.  
Human CA isoform IX (hCA IX) is produced in a limited number of normal tissues, while it is 
significantly overexpressed in many solid tumors. The enzymatic activity of hCA IX helps to maintain the 
pH of hypoxic tumor cells within normal range and lowers the pH level of the extracellular matrix, thus 
accelerating tumor growth and metastasis. Therefore, specific hCA IX inhibitors potentially could be used 
to suppress cancer growth and metastasis.  
Ideally, inhibition of CAs should be selective and targeted to specific isoforms. Medically used CA 
inhibitors have high affinity to most mammalian CA isoforms, thus making a long list of undesired side 
effects. In order to design an isoform selective inhibitor, accumulation of structural data is of crucial 
importance. Milligram amounts of pure enzyme are needed for structural studies and therefore efficient 
expression and purification protocols must be used. For hCA II highly efficient expression and purification 
system is already available and protein crystals can be produced easily. We have co-crystallized hCA II in 
complex with multiple CA inhibitors, not only giving further understanding for ligand-protein interactions, 
but also discovering a new type of CA ligands.  
At the time, there was only one protein production and purification system for hCA IX with a rather 
poor outcome. We managed to create a new expression and purification system for catalytic domain of hCA 
IX. Crystals were obtained with multiple CA inhibitors, not only notably increasing the available structural 
data about interactions of diverse inhibitors with the enzyme, but also providing a new perspective for 
further structural and functional studies of hCA IX.   
Kopsavilkums 
 
Ogļskābes anhidrāzes (CA) ir plaši izplatīti ar metāla jonu saistītie enzīmi, kas katalizē atgriezenisko 
reakciju, kurā ūdens molekula un ogļskābā gāze veido bikarbonāta un ūdeņraža jonus. Zīdītājos tās piedalās 
daudzos vitāli svarīgos procesos, kā piemēram pH regulēšanā un CO2 transportēšanā, tomēr dažu CA 
aktivitāte ir saistīta ar vairākām patoloģijām. 
Cilvēkos sastopamā CA II izoforma (hCA II) tiek saistīta ar glaukomu. hCA II enzimātiskā aktivitāte 
paaugstina bikarbonāta jonu koncentrāciju acī, tam seko Na+ jonu pieplūdums un ūdens plūsma gradienta 
virzienā, tādējādi paaugstinot intraokulāro spiedienu. Paaugstinātais intraokulārais spiediens bojā redzes 
nervu, kas var novest pie pilnīga redzes zuduma. hCA II inhibitori tiek izmantoti kā anti-glaukomas 
medikamenti, lai samazinātu slimības izraisītās sekas. 
Cilvēkos sastopamā ogļskābes anhidrāzes IX izoforma (hCA IX) tiek producēta nelielā skaitā veselo 
audu, bet tās ekspresija ir ievērojami palielināta daudzos audzēju veidos. hCA IX enzimātiskā aktivitāte 
palīdz uzturēt normālu pH līmeni hipoksiskajās audzēja šūnās, vienlaikus samazinot pH audzēju vidē, 
tādejādi paātrinot audzēju attīstību. Specifiski hCA IX inhibitori varētu tikt izmantoti, lai kavētu audzēju 
attīstību. 
Ideāli, CA inhibēšanai vajadzētu būt mērķētai uz specifisku izoformu. Medicīnā plaši izmantotie CA 
inhibitori ir ar augstu afinitāti pret vairumu zīdītājos sastopamo CA izoformu, līdz ar to, veidojot daudzas 
nevēlamas blaknes. Lai izveidotu izoformas selektīvu inhibitoru, ir būtiski akumulēt strukturālos datus. 
Strukturālo pētījumu priekšnosacījums ir miligramos mērāms attīrītā proteīna daudzums, līdz ar to, 
nepieciešama efektīva ekspresijas un attīrīšanas sistēma. hCA II esošā ekspresijas, attīrīšanas un 
kristalizācijas sistēma ir pietiekoši efektīva kristalogrāfijas vajadzībām. Mēs esam kokristalizējuši hCA II  
kompleksā ar vairākiem CA inhibitoriem, ne tikai dodot plašāku ieskatu ligandu-proteīnu mijiedarbībās, bet 
arī atklājot jaunu CA ligandu tipu. 
Promocijas darbu uzsākot, vienīgā aprakstītā hCA IX producēšanas un attīrīšanas sistēma bija ar vāju 
iznākumu. Mums izdevās izveidot jaunu hCA IX katalītiskā domēna ekspresijas un attīrīšanas sistēmu un 
iegūto proteīnu sakristalizēt ar dažādiem ligandiem. Iegūtie dati ne tikai ievērojami papildināja pieejamos 
strukturālos datus par hCA IX mijiedarbību ar dažādiem inhibitoriem,  bet arī sniedza jaunas iespējas hCA 
IX strukturālajiem un funkcionālajiem pētījumiem. 
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Abbreviations 
 
3D – three (3) dimensional 
Å – Ångström 
AMS - acute mountain sickness 
AZM – acetazolamide 
CA – carbonic anhydrase 
CCM - carbon dioxide concentration mechanism 
DMSO - dimethyl sulfoxide 
DNA – deoxyribonucleic acid 
DTT - dithiothreitol 
GI - gastrointestinal 
GPI - glycosylphosphatidylinositol 
HIF - hypoxia-inducible factor 
HRE - hypoxia-responsive element 
IC – intracytoplasmic domain 
IOP - intraocular pressure 
IPTG - isopropyl-β-D-thiogalactopyranoside 
kDa - kilodalton 
LB – Luria broth 
MBP - maltose binding protein 
Ni-NTA – nickel-nitrilotriacetic acid 
NMR – nuclear magnetic resonance 
OD – optical density 
PAGE – polyacrylamide gel electrophoresis 
PCR - polymerase chain reaction 
PDB - protein data bank 
PG – proteoglycan-like domain 
RNA – ribonucleic acid 
rpm – revolutions per minute 
RuBisCO - ribulose-1,5-bisphosphate carboxylase/oxygenase 
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SDS – sodium dodecyl sulfate  
TEMED - tetramethylethylenediamine 
TEV – tobacco etch virus  
TM – transmembrane segment 
ZBG – zinc binding group 
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Introduction 
Carbonic anhydrases are widespread in all domains of life. They are ancient enzymes, 
increasing their diversity with each next level of organisms along the course of evolution. There 
are at least 16 mammalian CA isoforms with variable localization in cells and tissue, but 
responsibility for the catalysis of the same reaction. All mammalian CA isoforms share relatively 
high sequence homology and conservative active sites. Although CAs perform physiologically 
important functions in the organism, activities of some of the mammalian CA isoforms are 
associated with various diseases. hCA II is a widespread CA isoform, but it is involved in 
manifestation of glaucoma and acute mountain sickness (AMS) symptoms and it is also 
overexpressed in gastrointestinal stromal tumor. hCA IX is expressed in a very limited number of 
normal tissues, but its highly overexpressed in many solid tumors. It has been assumed that 
enzymatic activity of hCA IX favors tumor growth, thus inhibition of this CA isoform could abate 
tumor spread.  
The first crystal structure of hCA II was solved in 1972. Now there are over 775 3D structures 
of hCA II available in the Protein Data Bank, making it one of the most structurally studied 
enzymes to date. Even so, selective hCA II inhibitors are yet to be achieved hCA II in many cases 
is considered an off-target isoform but, it is usually used as a primary test subject for new types of 
CA ligands.  
Although due to its high expression levels in many tumor types hCA IX is the main target 
for isoform selective CA drug design, up until 2015 there was only one protein 3D structure 
available in the PDB. Judging from the available data, no other research group has managed to 
obtain new hCA IX crystals, not even in the previously described crystallization conditions. Also, 
the described baculovirus expression system has a poor outcome, limiting the available 
experiments from one purification batch. In order to improve that, we decided to develop a new 
hCA IX catalytic domain expression and purification system, suitable for crystallization studies.  
The aim of this study was analysis of interactions of multiple ligands with the human carbonic 
anhydrase isoforms II and IX in order to use the results in rational, structure-based drug design. 
Workflow: 
1. Expression and purification of hCA II; 
2. Cloning, expression and purification of hCA IX; 
3. Crystallization of hCA II and hCA IX catalytic domain with multiple ligands; 
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4. Data collection of protein crystals; 
5. Analysis of the collected X-ray data, ligand modeling and protein-ligand interaction 
determination.  
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1. Literature review 
1.1. Carbonic anhydrases 
Carbonic anhydrases (CAs) are metalloenzymes that catalyze the reversible reaction:  
CO2+H2O ↔ HCO3- + H+ 
The reaction occurs within seconds also without a catalyst, but apparently this is not fast 
enough to meet the physiological needs of organism. CAs are among the fastest enzymes known 
catalyzing up to 1 000 000 reactions per second (Berg et al., 2002) (Table 1). CAs are widespread 
in many different organisms and mostly are responsible for vital processes in the organism. 
Meanwhile enzymatic activity of some CA isoforms is associated with various pathologies and 
their inhibition could slow down or even prevent specific diseases (Deitmer et al., 2015; Pinard et 
al., 2015).  
 
Table 1. Comparison of catalyzed reactions per second and rate enhancement of various enzymes. 
Adapted from (Berg et al., 2002). 
Enzyme Nonenzymatic 
half-life 
Uncatalyzed 
rate (kun,s
-1) 
Catalyzed rate 
(kcat, s
-1) 
Rate 
enhancement 
(kcat/kun) 
OMP decarboxylase 78 000 000 
years 
2.8 x 10-16 39 1.4 x 1017 
Staphylococcal 
nuclease 
130 000 years 1.7 x 10-13 95 5.6 x 1014 
AMP nucleosidase 69 000 years 1.0 x 10-11 60 6.0 x 1012 
Carboxypeptidase A 7.3 years 3.0 x 10-9 578 1.9 x 1011 
Ketosteroid 
isomerase 
7 weeks 1.7 x 10-7 66 000 3.9 x 1011 
Triose phosphate 
isomerase 
1.9 days 4.3 x 10-6 4300 1.0 x 109 
Chorismite mutase 7.4 hours 2.6 x 10-5 50 1.9 x 106 
Carbonic anhydrase 5 seconds 1.3 x 10-1 1 000 000 7.7 x 106 
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1.2. CA enzymatic reaction 
CAs are metalloenzymes, active site of which in most cases contain a Zn2+ ion, coordinated 
by four ligands. Zn2+ ion can be coordinated by various residues (histidine, cysteine, etc.) (Laitaoja 
et al., 2013), but in most CA isoforms it is coordinated by nitrogen atoms of three histidine 
imidazole rings while the fourth coordination site is occupied by a water molecule (Fisher et al., 
2007; Supuran, 2012) (Figure 1.). 
 
Figure 1. Coordination of zinc ion in human carbonic anhydrase isoform IX (PDB code 
6FE2). The figure was prepared with the PyMOL Molecular Graphics System, Version 2.0 
Schrödinger, LLC. 
 
The reaction mechanism of CO2 anhydrase is shown in Figure 2. When a water molecule is 
bound to the Zn2+ ion, it dissociates to OH- group as a result of proton transfer. OH- group makes 
a nucleophilic attack to electrophilic CO2 forming a HCO3
- ion. HCO3
- stays weakly bound to Zn2+ 
ion until it is further replaced by a water molecule and the reaction cycle can start over again (Fisher 
et al., 2007; Supuran, 2012) (Figure 2.).   
14 
 
 
Figure 2.  Enzymatic reaction of carbonic anhydrase. Adapted from (Supuran, 2012). 
1.2.1. His64 proton shuttle 
In case of CAs, speed of enzymatic reaction can be so vast that it becomes limited by substrate 
diffusion (Lindskog, 1997). A specific proton transfer mechanism greatly increases proton 
movements near the active site and allows the enzyme to bind a new substrate more quickly, 
therefore increasing the reaction speed (Maupin & Voth, 2007; Fisher et al., 2007; Tu et al., 2002). 
Movement of His64 (CA II numbering) side chain rotamer is significant for speed enchantment of 
catalytic reaction and has been proven by various kinetic measurements using hCA II His64→Ala 
mutants. Enzymatic reaction in those mutants ensued 10-50x slower than in the wild type hCA II 
(Tu et al., 1989; Roy & Taraphder, 2006). X-ray data has demonstrated that side chain of His64 
has two alternative rotamers – “in” (closer to the active center) and “out” (further from the active 
center). As His64 “in” position is still too far from Zn2+ ion (~7.5 A) or Zn2+ bound water molecule 
it cannot carry out its proton transfer function directly. His64 proton transfer is achieved by a 
network of water molecules, forming a bridge in order to transfer the protons. His64 at its “in” 
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position obtains the proton from a nearby located water molecule and moves to the “out” position 
releasing the proton (Fisher et al., 2005) (Figure 3.). 
 
Figure 3. Solvent network of hCA II active site pocket and His64 proton shuttle mechanism 
Adapted from (Shimahara et al., 2007). 
 
1.3. CA classification 
Carbonic anhydrases are divided into 7 classes (α-, β-, γ-, δ-, ζ-, η-, and θ-CAs) (Capasso & 
Supuran, 2015; Kikutani et al., 2016; Supuran & Capasso, 2015; Aspatwar et al., 2018). CAs are 
structurally very diverse but the conjunctive element is the same catalytic reaction. Therefore, 
carbonic anhydrases are good examples of convergent evolution (Hewett-Emmett & Tashian, 
1996; Liljas & Laurberg, 2000). CAs are evolutionarily ancient enzymes and pose higher and 
higher diversity along with increasing complexity of organisms (Banerjee & Deshpande, 2016).  
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1.3.1. β-CA 
The β-class carbonic anhydrases are abundant among lower eukaryotes, prokaryotes, archaea 
and plants (Rowlett, 2010). Catalytic activity of β-CAs is relevant in photosynthesis. β-CAs help 
to regulate chloroplast pH levels and the CO2 concentration mechanism (CCM) near RuBisCO 
(Bhat et al., 2017) (Figure 4.). 
 
 
Figure 4. Role of the β-CAs explained involving RuBisCO. Adapted from (Bhat et al., 2017). 
 
β-CAs are associated with ability of some plants to overcome cold temperatures and low light 
conditions and they also participate in immune responses to pathogens (Siedlecka et al., 1999). 
Structurally, β-CAs resemble a Rossmann fold, in which a central four-stranded parallel beta sheet 
with additional antiparallel strand is surrounded by alpha helices from both sides (Figure 5.). 
Catalytic zinc ion in β-CAs is coordinated by two cysteines and one histidine. Occasionally, Zn2+ 
ion in β-CAs can be coordinated by a fourth residue – aspartate, which renders the enzyme inactive 
at pH values below 8, but above pH 8.3 aspartate gets replaced by a water molecule thus re-
activating the enzyme. (Huang et al., 2011; DiMario et al., 2017).  
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Figure 5. Tertiary structures of α-CA (panel A, PDB code 1CA2), β-CA (panel B, PDB code 
1I6P) and γ-CA (panel C, PDB code 1QRG). Zn2+ ion coordinating residues are indicated. The 
figure was prepared with the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
 
Beta class CAs are found also in pathogens like Salmonella typhimurium, Mycobacterium 
tubercolusis and Heliobacter Pylori (Rowlett, 2010). Since β- CAs are involved in important 
functions of pathogens, specific inhibition could have antibacterial effect (Vullo et al., 2018). 
Antibacterial properties of CA inhibitors have been detected in studies on S. Typhimurium 
(Zimmerman & Ferry, 2008), potentially enabling development of CA-targeted antibiotics. 
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1.3.2. γ-CA 
The γ-CA class is widely distributed in all three domains of life, however only a few of γ-
CA enzymes have been studied kinetically or structurally, largely from Archaea domain (Ferry, 
2010). 
Structurally, monomers of γ-CAs are beta helices. Three monomers form a functionally 
active trimeric enzyme with three active sites located in between the monomers. Active site 
architecture of γ-CAs is somewhat similar to mammalian CAs, since Zn2+ is being coordinated by 
three histidines (Pena et al., 2010). Tested sulfonamides display weaker affinity to γ-CA than 
mammalian CA isoforms, which can be explained by different pocket conformation at the enzyme 
active site (Zimmerman & Ferry, 2008). 
1.3.3. Other CA classes 
δ- CA class can be found in marine diatoms (Del Prete et al., 2014a; Lapointe et al., 2008). 
ε- CA class has been identified in carboxysomal shell (So et al., 2004) of cyanobacteria and now 
are considered being highly modified β-CAs. η- family of CAs has been found in Plasmodium 
species and their enzymatic activity is considered to favor malaria (Reungprapavut et al., 2004; 
Krungkrai & Krungkrai, 2011), therefore they might be important targets for anti-malarial drugs. 
θ- class was recently identified in marine diatoms (Kikutani et al., 2016). ζ- class CAs also have 
been identified in marine diatoms. Structurally they somewhat resemble β-CAs both in respect to 
overall structure and metal coordination. ζ- class CAs are unique in their ability to use cadmium 
ion instead of zinc ion in their active sites, which might be an evolutionary advantage in zinc-
depleted environments, often found in oceans (Alterio et al., 2015a). 
1.3.4. α-CA 
α-CA isoforms are found in many diverse organisms - algae, some bacteria and vertebrates, 
including mammals. α-CAs are structurally similar and their monomers are composed of seven 
alpha helices and 10 beta strands (Aggarwal et al., 2013). There are 16 α-CA isoforms identified 
in humans (hCAs) (Supuran, 2018a) with various localizations in the cell – cytosolic, 
mitochondrial, membrane-associated and secreted. Different hCA isoforms display remarkably 
different speeds of catalyzed reaction (Singh, 2018; Pinard et al., 2015) (Table 2). For example, 
CA Va isoform is considerably less active than hCA II, probably because of His64 → Ala mutation 
which disrupts the proton transfer mechanism and significantly lowers enzymatic activity (Heck et 
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al., 1996). CA VIII, X and XI isoforms are enzymatically inactive (carbonic anhydrase related 
proteins, CARPs) and their function in cell remains unclear, but it has been demonstrated that 
overexpression of CARPs in certain tissues corelate with cancer (Aspatwar et al., 2010). hCA 
isoforms are mostly involved in vital processes like pH and CO2 homeostasis, bone resorption, 
calcification and other (Frost, 2014), but activity of some hCA isoforms are associated with various 
diseases (Pinard et al., 2015).  
 
Table 2. Characteristics of hCA isoforms - catalyzed reaction speeds, current number of PDB 
entries, localization in cell and tissue. Adapted from (Supuran, 2008b). 
Isoform Kcat 
PDB 
entries 
Location (cell) Location (tissue/organ) 
hCA I 2.0 × 105 32 cytosol Red blood cells, GI tract 
hCA II 1.4 × 106 775 cytosol 
Red blood cells, lung, 
eye, brain, osteoclasts, 
GI tract. kidney, testis 
hCA III 1.0 × 104 6 cytosol 
Skeletal muscle, 
adipocytes 
hCA IV 1.1 × 106 12 
Membrane bound, 
extracellularly located 
catalytic domain 
GI tract, lung, kidney, 
colon, pancreas, brain 
capillaries, heart muscle 
hCA Va 2.9 × 105 
4 
(murine) 
mitochondria liver 
hCA Vb 9.5 × 105 - mitochondria 
kidney, heart and skeletal 
muscle, spinal cord, 
pancreas, GI tract 
hCA VI 3.4 × 105 1 secretory 
Salivary and mammary 
glands 
hCA VII 9.5 × 105 6 cytosol CNS 
hCA IX 3.8 × 105 9 
Transmembrane, 
extracellularly located 
catalytic domain 
GI tract, several tumours 
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hCA XII 4.2 × 105 18 
Transmembrane, 
extracellularly located 
catalytic domain 
Eye, reproductive 
epithelia, renal, 
intestinal kidney, several 
tumours 
hCA XIII 1.5 × 105 16 cytosol 
Lung, brain, kidney, 
reproductive tract, gut 
hCA XIV 3.1 × 105 4 
Transmembrane, 
extracellularly located 
catalytic domain 
Kidney, heart, skeletal 
muscle, brain, liver 
 
Most of the mammalian CA isoforms are cytosolic, CA Va/Vb are localized in mitochondria 
while CA IX, CA XII and CA XIV are transmembrane proteins with an extracellular catalytic 
domain (Whittington et al., 2001; Alterio et al., 2009). CA IV is a GPI-anchored CA isoform with 
extracellular catalytic domain (Schneider et al., 2013). CA VI is the only α-CA isoenzyme which 
is secreted and can be found in saliva (Kivela et al., 1999). 
All of the human α-CA isoforms have a relatively high sequence identity and it ranges from 
23.1% to 60.5% (Pinard et al., 2015) (Table 3). Active site forming residues for hCA isoforms are 
highly conservative and it is the main problem for design of isoform selective hCA inhibitors  
(Supuran, 2012). 
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Table 3. Human carbonic anhydrase sequence homology in percent (lower left) and number 
of conserved residues (upper right). Adapted from (Pinard et al., 2015). 
 
 hCA 
I 
hCA 
II 
hCA 
III 
hCA 
IV 
hCA 
Va 
hCA 
Vb 
hCA 
VI 
hCA 
VII 
hCA 
IX 
hCA 
XII 
hCA 
XIII 
hCA 
XIV 
hCA I - 158 141 78 126 128 82 132 83 91 154 85 
hCA II 60.5 - 152 88 133 138 90 147 85 89 157 96 
hCA III 54.2 58.5 - 82 120 117 87 130 80 86 151 90 
hCA IV 30.0 33.5 31.2 - 89 93 97 90 84 91 84 62 
hCA VA 48.1 50.8 45.4 23.6 - 184 93 131 83 84 124 88 
hCA VB 46.9 51.9 43.5 23.1 58.7 - 82 134 89 79 131 88 
hCA VI 31.9 33.5 32.3 27.0 27.9 24.4 - 93 107 104 90 106 
hCA VII 50.8 56.2 49.6 31.8 48.5 49.2 34.9 - 95 103 139 97 
hCA IX 33.1 34.2 31.1 27.2 31.9 32.7 38.9 37.0 - 101 90 113 
hCA XII 35.8 34.2 32.3 28.1 31.6 29.7 38.0 38.0 38.9 - 91 123 
hCA XIII 59.2 59.6 57.7 28.2 46.2 47.7 33.2 52.7 35.0 34.7 - 98 
hCA XIV 34.2 35.8 34.2 29.0 31.9 29.0 35.8 36.0 44.4 46.0 37.4 - 
 
1.4. Active site of α-carbonic anhydrases 
The active site of hCA is amphipathic, possessing both hydrophobic and polar parts 
(Krishnamurthy et al., 2008). It is thought that this is due to the extremely different properties of 
substrate vs products – CO2 is a hydrophobic gas, while HCO3- and H+ highly soluble ions. 
Therefore, CO2 enters or exits the active site through the hydrophobic part while ions use the polar 
part. This property can be used in the design of specific “dual-tail” inhibitors occupying both parts 
of the active site. The goal for providing selectivity between similar isoforms is to orient the tails 
of ligands towards the region which differs most between target isoforms (Casey et al., 2004). 
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Table 4. Active site forming residues in hCAs (CA II numbering). Residues coordinating 
Zn2+ ion are marked in green, most variable residues between isoforms are marked in red. Adapted 
from (Tars & Matulis, in press). 
Residue 
 
Isoform 
I II III IV Va Vb VI VII IX XII XIII XIV 
5 W W W W W Y W W W W W W 
7 Y Y Y Y W Y Y Y Y Y Y Y 
60 I L L Q W W V T R T S H 
62 N N N N N N N N N N N N 
64 H H K H Y Y H H H H H H 
65 S A T S L S T S S S S T 
67 H N R M Q L Q Q Q K N Q 
91 F I R K K K Q K L T R A 
92 Q Q Q Q Q Q Q Q Q Q Q Q 
94 H H H H H H H H H H H H 
96 H H H H H H H H H H H H 
119 H H H H H H H H H H H H 
121 A V V V V V V V V V V V 
131 L F F V Y F Y F V A F L 
135 A V L Q V A Q A L S A A 
141 L L I I L L L L L L L L 
143 V V V V V V V V V V V V 
198 L L F L L L L L L L L L 
199 T T T T T T T T T T T T 
200 T T T T T T T T T T V T 
202 P P P P P P P P P P P P 
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Table 4. shows that only a few residues within the active site of hCAs have a relatively high 
diversity between hCA isoforms, making achieving of selectivity a challenging task. A very 
important factor for isoform selective drug design is an available three-dimensional (3D) model of 
the target protein. Most ligands are modeled based on known 3D structures, combined with 
additional data for ligand-protein interactions (Pinard et al., 2015).  
 
 
 
 
Figure 6. Comparison of active site pockets of hCA II (PDB code: 1CA2) and hCA IX (PDB 
code: 3IAI). Protein is visualized as a surface model, key residues forming the active site pocket 
are indicated. Residue labels in red indicate differences between hCA II and hCA IX. The figure 
was prepared with the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
 
Although active centers of all hCA isoforms are very similar there are some key residues 
which can be targeted for selectivity (Figure 6.). Some differences in the structure of active sites 
between CA isoforms can be also found in conservative regions, since the surrounding variable 
residues to some extent alter the overall 3D structure of the active site. Novel ligands can be 
modeled using protein–ligand docking software, trying to orient the ligand to the most diverse 
region between all α-CA isoforms (Tuccinardi et al., 2007).  
 
1.5. Methods for structure determination of carbonic anhydrase  
Even if the designed inhibitor binds well to the target enzyme, it is advisable to check the 
exact binding mode experimentally. Currently the most popular method for determination of 
protein-ligand interactions is X-ray crystallography. In case of monomeric CAs presumably NMR 
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could be used as well, but dimeric hCAs, like hCA IX or hCA XII are too large for analysis by 
solution NMR. The latest developments in cryo-electron microscopy (cryo-EM) allow structure 
determination at atomic resolution, but opposite to NMR currently it can be used only for large 
structures with size of at least 100 kDa. Neutron diffraction is yet another method of structure 
determination. In fact, hCA II is one of very few enzymes for which neutron diffraction structures 
have been determined. Although neutron diffraction has an advantage of revealing hydrogen 
positions, it requires extremely large crystals and very long data collection times, therefore in 
practice it can be successfully applied in very limited occasions.  
To determine a 3D structure using x-ray crystallography the protein has to be crystallized 
first. Finding crystallization conditions is arduous and not every protein can be crystallized. Some 
hCA isoforms can be crystallized relatively efficiently, for example hCA II is easy to work with, 
as it can be easily produced in E. coli, it is highly soluble, can be purified without affinity tags and 
it crystallizes in a couple of days. Diffraction of hCA II crystals typically reaches atomic resolution 
(up to 0.9 Å) (Behnke et al., 2010; Avvaru et al., 2010). It is one of the most studied enzymes in 
the field of structural biology, with more than 775 structures available in the PDB. However, 
crystallization of other hCA isoforms is more challenging. Up until 2015 there was only one 3D 
structure available in the PDB for one of the main targets in CA drug design – tumor associated 
hCA IX (Alterio et al., 2009).  
 
1.6. hCA II 
hCA II is one of the 16 hCA isoforms and is encoded by the CA 2 gene found in 8q21.2 
region of 8th chromosome (Nakai et al., 1987). hCA II is a relatively widespread cytosolic CA 
isoform found in red blood cells, kidney, osteoclasts, eye, GI tract, lung, brain and elsewhere 
(Smith et al., 1999). hCA II has a fold and metal coordination pattern typical for all α-CAs (Avvaru 
et al., 2010) (Figure 7.). 
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Figure 7. Tertiary structure of human carbonic anhydrase isoform II (PDB code: 3KS3). Zn2+ 
coordinating histidine residues are indicated. The figure was prepared with the PyMOL Molecular 
Graphics System, Version 2.0 Schrödinger, LLC. 
 
hCA II is associated with various diseases by interfering with ion concentrations and 
influencing flow of water molecules. hCA II is associated with glaucoma (Kaur et al., 2002), acute 
mountain sickness (Taylor, 2011) and gastrointestinal stromal tumor (Parkkila et al., 2010). 
However, in most cases regarding the drug design, hCA II is considered an off-target isoform, since 
it is abundant in very many tissue types.  
1.6.1. hCA II associated diseases 
Glaucoma is a group of diseases characterized by a damage to optical nerve, which can lead 
to the loss of vision. The most important risk factor for development of glaucoma is increased 
intraocular pressure (IOP). Aqueous humor depends on the bicarbonate ion concentration in the 
eye. Human carbonic anhydrases (II, IV, XII) increase the bicarbonate ion concentration in the 
aqueous humor, followed by increase of Na+ ion intake, which results in water flow along the 
gradient, thus increasing IOP (Mincione et al., 2008). Increased IOP damages the eye nerve and 
eventually leads to complete blindness (Maren, 1967). Although there is no cure for glaucoma, CA 
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inhibitors are used to ease the symptoms. Use of CA inhibitor acetazolamide (AZM) results in 25-
30% decrease of the IOP, therefore lowering symptoms of glaucoma (Mincione et al., 2008). In 
medicine, the widely used CA inhibitor AZM is being sold under the trade name Diamox, treating 
various α-CA related diseases, including glaucoma (Jafarzadeh et al., 2014; Van Berkel & Elefritz, 
2018). AZM has a poor selectivity and inhibits most of the human carbonic anhydrases, therefore 
common side effects include various symptoms like dizziness, lightheadedness, blurred vision, dry 
mouth, loss of appetite, nausea, vomiting, headache, diarrhea and many others (Katayama et al., 
2002). 
Enzymatic activity of hCA II is involved in acute mountain sickness (AMS) with symptoms 
present from approximately 2500 m (Taylor, 2011). High altitude caused hypoxia includes 
symptoms like troubled sleep, headache, dizziness, mental problems, weight loss, weakness and 
others. The exact mechanism of how CA inhibitor AZM reduces AMS symptoms is not known yet, 
but it has been associated with CA inhibition in the kidney (Leaf & Goldfarb, 2007). 
Diuretics: it is known that inhibition of hCA II and membrane bound hCA IV and hCA XIV 
in humans work as diuretics (Supuran, 2008a; Carta & Supuran, 2013). By inhibiting those 
isoforms the available protons for the Na+/H+ antiporter, which regulate proton concentration in 
cell, decreases, resulting in transport of NaHCO3 from the tubular lumen to the interstitial space, 
which increases water concentration and therefore induces diuretic effects (Puscas et al., 1999; 
Carta & Supuran, 2013).   
 Enzymatic activity of hCA II is involved in pH regulation in osteoclasts, therefore it is 
essential for optimal bone resorption (Kumar et al., 2007). It has been proved that CA 2 gene 
deficiency in humans is related with osteopetrosis (Shah, et al., 2004). Therefore, hCA II inhibitors 
are used to treat osteoporosis (Pierce et al., 1991). 
hCA II is overexpressed in gastrointestinal stromal tumors and therefore could be used as 
a biomarker for this particular type of cancer, or even as a target for inhibitors to slow tumor spread 
via destabilization of cancer cell pH (Parkkila et al., 2010).  
 
1.7. hCA IX 
Human carbonic anhydrase isoform IX (hCA IX) is encoded by the CA9 gene found in the 
p12-p13 region of chromosome 9 (Nakagawa et al., 1998). CA9 gene transcription is regulated by 
hypoxia-inducible transcription factor HIF-1 (Chiche et al., 2010; van den Beucken et al., 2009), 
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which is activated upon hypoxic conditions.  HIF-1 is responsible for transcriptional control of 
CA9 gene by binding to the CA9 hypoxia-responsive element (HRE), which activates the CA9 
promoter and gene expression (Kaluz et al., 2009). 
hCA IX is a transmembrane protein and consists of 4 domains (Alterio et al., 2009) (Figure 
8.). 
  
 
Figure 8. Proposed model of full length human carbonic anhydrase isoform IX. Adapted from 
(Tars & Matulis, in press). 
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Proteoglycan-like domain (PG) is an N-terminal component of hCA IX. It is unique in the 
hCA IX isoform and is not found in any other mammalian CAs. PG domain owes its name to some 
sequence similarity to aggrecan, which is a part of proteoglycan assembly. However, covalently 
linked carbohydrates have not been observed in CA IX PG domain, except for a single O-
glycosylation site. Structurally, PG domain seems to be disordered with some parts possibly 
adapting polyproline type II helix conformation (Langella et al., 2018). Several functions have been 
attributed to PG domain. It has been demonstrated that PG domain is responsible for cancer cell 
adhesion, migration and spreading (Zavadova & Zavada, 2005; Csaderova et al., 2013). PG domain 
also influences the catalytic activity of enzyme. PG-less CA IX is roughly 2-3 times less active 
(Hilvo et al., 2008) and the optimum pH value of full-length enzyme is shifted from 7.0 to 6.5, thus 
making CA IX more efficient in acidic tissue, typical for hypoxic conditions (Innocenti et al., 
2009).  
The catalytic domain has relatively high amino acid homology to other mammalian CA 
isoforms and the obvious role of this domain is to perform the catalytic reaction (Hilvo et al., 2008). 
Transmembrane α helix (TM) is responsible for anchoring the catalytic domain (Morgan et al., 
2007), while the intracellular fragment (IC) role is associated with location of the catalytic domain 
in the cell (Hulikova et al., 2009). No direct experimental data is available regarding IC structure, 
but modelling studies suggest that part of IC might be in helical conformation (Buonanno et al., 
2017). IC domain has three phosphorylation sites - T406, S411, and Y412. The first two seem to 
regulate the enzymatic activity of CA IX, while the last one is involved in EGFR-induced signal 
transduction to PI3/Akt kinase pathway. IC tail has also been shown to interact with cullin-
associated NEDD8-dissociated protein 1 (CAND1). It appears that CAND1 is stabilizing CA IX 
structure, since cells with lower CAND1 expression also have lower CA IX content (Buonanno et 
al., 2017).  
Dimer formation is surprisingly different for hCA IX and hCA XII, although they are 
structurally similar and both are transmembrane proteins expressed in similar tissues. Another 
isoform - hCA VI also forms a dimer and its oligomerization form is very different from both hCA 
IX and hCA XII (Figure 9.). Dimer forming for hCA VI is stabilized by 11 hydrogen bonds and 
van der Waals forces (Pilka et al., 2012). In contrast, hCA XII is stabilized by 19 hydrogen bonds 
(Whittington et al., 2001) and hCA IX by 2 hydrogen bonds and one intermolecular disulfide bond. 
Available structural data has shown that the absence of a disulfide bond does not interrupt 
oligomerization of hCA IX (Alterio et al., 2009; Leitans et al., 2015).  
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Active site cavities in hCA IX and hCA XII dimers are relatively far from each other, but in 
case of hCA VI entrances of both active site cavities are oriented facing each other. 
 
Figure 9. Superposed dimer structures of catalytic domains of hCA VI (purple, PDB code 
3FE4), hCA IX (green, PDB code 6FE2) and CA XII (blue, PDB code 1JCZ). The figure was 
prepared with the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
 
hCA IX is overexpressed in many solid tumors including renal cell carcinoma (Bismar et al., 
2003), breast cancer (Chia et al., 2001) and others (Figure 10.). Enzymatic activity of hCA IX 
favors tumor metastasis (Supuran, 2012; Chiche et al., 2009) and high expression of hCA IX 
correlates with poor prognosis and reduced disease-free interval following therapy (Bui et al., 
2003). In limited amounts hCA IX can also be found in several normal tissues, notably 
gastrointestinal tract (Mahon et al., 2015).  
Knockout CA9 gene in mice in homozygous animals results in development of mild gastric 
hyperplasia (Gut et al., 2002). However, it does not disrupt mice development and gastric juice pH 
and secretions are kept at normal levels. Judging from these experiments, it has been promoted that 
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the disruption of CA9 gene does not lead to serious abnormalities in development and 
sustainability, leading to concept that selective hCA IX inhibition also would not cause serious side 
effects (Leppilampi et al., 2005; Pan et al., 2006). 
  
 
 
Figure 10. Expression of CA IX in various types of human cancer (grey bars) and normal 
tissue (striped bars). Adapted from (Mahalingam et al., 2018). 
1.7.1. hCA IX targeting in anti-tumour drug design 
 Specific presence of CA IX on the surface of tumour cells can be targeted in two distinct 
ways. First, enzymatic activity of CA IX can be inhibited by small molecules, therefore slowing 
the catalytic reaction. Second strategy is to use CA IX as a cancer cell-targeting molecule. For 
example, specific anti-CA IX antibodies can mediate cancer cell destruction by antibody-dependent 
cell-mediated cytotoxicity, complement-dependent cytotoxicity and antibody-dependent cellular 
phagocytosis (Chang et al., 2015). Several monoclonal anti-CA IX antibodies have been shown to 
reduce tumour size in animal models. Anti-CA IX monoclonal antibody Girentuximab (known also 
as G250) displayed promising results in Phase I and Phase II clinical trials (Bleumer et al., 2004) 
but failed to display significant benefit in Phase III trials (Haas et al., 2017).  
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1.8. CA inhibitors 
1.8.1. Ligand classification 
Ligand binding to the active center of enzyme can lower the enzymatic activity. In principle 
it can be done in several ways - by interaction with key residues or co-factors required for catalytic 
activity, by changing the conformation of the active site or by slowing/blocking diffusion of 
substrates or products near the active site – (Srinivasan et al., 2019).  “Classical” CA inhibitors are 
compounds that bind directly to the Zn2+ ion displacing the water molecule and therefore 
preventing the catalytic reaction. Sulfonamides are by far the most popular class of CA inhibitors. 
Like many classical CA inhibitors, sulfonamides are made of a zinc binding group, linker and a tail 
moiety (Pinard et al., 2015) (Figure 11.).   
 
 
Figure 11. Schematic representation of classical CA inhibitors. Adapted from (Pinard et al., 
2015). 
 
In the case of sulfonamides ZBG is SO2NH2, where NH2 moiety interacts with Zn
2+, also 
forming hydrogen bond with conservative α-CA residue Thr199 (Chakravarty & Kannan, 1994) 
(Figure 12.). The linker usually is an aromatic ring, it has little (if any) interaction with active site 
residues and mostly functions as a connector to the tail moiety. Tail moieties are very diverse, 
mostly modeled to target specific regions of active site (Scozzafava et al., 1999; Pinard et al., 2015).   
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Figure 12. Binding mode of acetazolamide within the active site of hCA II (PDB code 3HS4). 
The figure was prepared with the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, 
LLC. 
 
It was discovered that the artificial sweetener saccharin can also inhibit some of the α-CA 
isoforms (Figure 13.). The inhibition mechanism of saccharine is similar to the sulfonamide 
binding mode - it also blocks the binding of water molecule to the Zn2+ ion. Although the binding 
mode is similar, differences in orientation of bound saccharin from sulfonamides can be useful for 
design of ligand tail orientation (Köhler et al., 2007).  
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Isoform KI [nM] 
 Acetazolamide Saccharin 
hCA I 250 18540 
hCA II 12 5950 
hCA IV 74 7920 
hCA Va 63 10060 
hCA Vb 54 7210 
hCA VI 11 935 
hCA VII 2.5 10 
hCA IX 25 103 
hCA XII 5.7 633 
hCA XIV 41 773 
 
Figure 13. Inhibition constants of acetazolamide and saccharin on human carbonic anhydrase 
isoforms (left) (Köhler et al., 2007). Binding mode comparison of acetazolamide (PDB code 3HS4) 
and saccharine (PDB code 2Q1B) (right). The figure was prepared with the PyMOL Molecular 
Graphics System, Version 2.0 Schrödinger, LLC. 
 
Sulfocoumarin type inhibitors present a different binding mode. Sulfocoumarins bind to CAs 
in hydrolyzed form and do not replace the zinc-bound water molecule, but interact with it via a 
hydrogen bond, thereby blocking the access of CO2 molecule (Tars et al., 2013) (Figure 14.). 
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Figure 14. Binding mode of sulfocoumarin within the active site of carbonic anhydrase. 
Adapted from (Tars et al., 2013). The figure was prepared with the PyMOL Molecular Graphics 
System, Version 2.0 Schrödinger, LLC. 
1.8.2. Novel aspects for the CA inhibitor design  
Design of dual tail inhibitors is another useful approach in order to achieve isoform selective 
inhibitors (Figure 15.). This strategy makes use of both polar and hydrophobic parts of CA active 
site. If a compound contains both hydrophobic and polar tails it could be targeted as potentially 
covering more surface and gaining selectivity for the isoform (Tanpure et al., 2015).  
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Figure 15. Dual tail ligand approach in CA drug design. Adapted from (Tanpure et al., 2015). 
 
Many factors must be noted in designing of inhibitors. The inhibitor has to be with high 
selectivity and affinity to the target isoform and has to be able to cross the plasma membrane in the 
case of cytosolic isoforms. Often the designed compounds have poor solubility in water, which can 
make further studies difficult (Scozzafava et al., 1999).  
Specificity of CA inhibitors can also be modulated by their capability to cross plasma 
membrane. Most of the CA isoforms are cytosolic, while tumor associated CA IX and CA XII are 
extracellular. Membrane impermeability can be achieved by addition of high molecular weight 
compounds that are too big for the membrane penetration (bulky compounds), charged molecules 
that are incapable of passing into the cytosolic environment (fluorescently labeled or cationic 
compounds) or glycoconjugates. In this way it is possible to partially address selectivity problems 
in respect to most of the CA isoforms (Mahon et al., 2015) (Figure 16.). 
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Figure 16. Classification of carbonic anhydrase inhibitors by their ability to cross plasma 
membrane. Adapted from (Mahon et al., 2015). 
1.8.3. Approved CA inhibitor medications and ongoing clinical trials 
Currently the most widely used CA inhibitor in medicine is acetazolamide, but it has poor 
selectivity and it strongly inhibits most of the human carbonic anhydrase isoforms (Hilvo et al., 
2008) (Table 5). Dorzolamide (Serle, 1994), Methazolamide (Gudmundsdóttir et al., 2000), 
ethoxzolamide (García-Fernández et al., 2013), Dichlorphenamide (Kanski et al., 1968), 
Brinzolamide (Lusthaus & Goldberg, 2017), Topiramate (Aminlari et al., 2008), Sulpiride (Souza 
et al., 2008) and Zonisamide (De Simone et al., 2005) are other approved acetazolamide-like 
medications, with little specificity regarding different CA isoforms and mostly used to treat hCA 
II related diseases. For example, dorzolamide is a topical drug, which can be used as eye drops in 
case of glaucoma. Dorzolamide was developed to circumvent systemic side effects of 
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acetazolamide, which has to be taken orally. Dorzolamide has a reputation of first drug used for 
human therapy, discovered by structure-aided drug design. 
Some other CA inhibitors have reached clinical trials. Indisulam is a chloroindolyl 
sulfonamide. It showed promising results in Phase I trial (Raymond et al., 2002), but Phase II trial 
was terminated in 2016 (Talbot et al., 2007).   
 
Table 5. Inhibition constants of most popular CA inhibitors. Adapted from (Supuran, 2008b). 
KI(nm) hCA I hCA 
II 
hCA III hCA IV hCA 
VA 
hCA 
VB 
hCA 
VI 
hCA 
VII 
hCA 
IX 
hCA 
XII 
mCA 
XIII 
hCA 
XIV 
Acetazolamide 250 12 2x105 74 63 54 11 2.5 25 5.7 17 41 
Methazolamide 50 14 7x105 6200 65 62 10 2.1 27 3.4 19 43 
Ethoxzolamide 25 8 1x106 93 25 19 43 0.8 34 22 50 2.5 
Dichlorphenamide 1200 38 6.8x105 15000 630 21 79 26 50 50 23 345 
Dorzolamide 50000 9 7.7x105 8500 42 33 10 3.5 52 3.5 18 27 
Brinzolamide 45000 3 1.1x105 3950 50 30 0.9 2.8 37 3.0 10 24 
Indisulam 31 15 10400 65 79 23 47 122 24 3.4 11 106 
Topiramate 250 10 7.8x105 4900 63 30 45 0.9 58 3.8 47 1460 
Sulpiride 12000 40 10600 6.5x105 174 18 0.8 3630 46 3.9 295 110 
Zonisamide 56 35 2.2x106 8590 20 6033 89 117 5.1 11000 430 5250 
SLC-0111 5080 960 - 286 - - - - 45 4.5 - - 
 
Ureido-benzenesulfonamide compund SLC-0111 is now in Phase Ib/II clinical trials as anti-
tumour drug candidate (Supuran, 2018b). Judging from the available data in literature, compound 
SLC-0111 has been tested in vitro for inhibition potential against hCAs I, II, IX and XII (Carta et 
al., 2017). Although SLC-0111 is a weaker hCA IX inhibitor than acetazolamide, it has 
significantly decreased affinity to isoforms I and II, which are considered as off-target isoforms in 
most cases (Pinard et al., 2015). Affinity to hCA XII can be considered as a bonus. hCA XII is 
another tumor associated hCA isoform and it has been proven that hCA XII works as a 
compensating mechanism in tumor cells if hCA IX activity is lowered (Chiche et al., 2009). 
However, compared to hCA IX, hCA XII has a wider distribution in normal tissue. 
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2. Materials and Methods 
2.1. E.coli strains 
E.coli RR1: F- leuB6 proA2 thi-1 araC14 lacY1 galK2 xyl-5 mtl-1 rpsL20 (Strr) glnV44 recA+ 
Δ(mcrC-mrr) (Stratagene, USA) 
E.coli JM109: F’ traD36 proAB laclq Δ(lacZ)M15/ endA1 rec A1 gyrA96(Nalr) thi 
hsdR17(rk
-mk
+) relA1 supE44 Δ(lac-proAB) (Stratagene, USA) 
E.coli BL21 (DE3): F– ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3 [lacI lacUV5-T7 gene 1 ind1 
sam7 nin5]) (Stratagene, USA) 
Pichia pastoris GS115 his4 (Stratagene, USA) 
2.2. Expression vectors 
In this work pETDuet-1, pRSFDuet-1 and pPIC3.5K vectors were used (Invitrogen, USA).  
2.3. Genes 
Genes were obtained from gene synthesis service company GenScript (Japan). 
2.4. Agarose gel electrophoresis 
Agarose gel electrophoresis was performed using 1 % agarose (Thermo Fisher Scientific, 
USA) gels in 1x TAE buffer (1 mM EDTA, 40 mM Tris, 20 mM acetic acid) with additional 1 
μg/mL ethidium bromide solution (Merck, Germany). 
2.5. DNA fragment purification from agarose gel  
DNA fragments were extracted from the agarose gel by using GeneJET Gel Extraction Kit 
(Thermo Fisher Scientific, USA) reagents and manufacturer provided user manual. 
2.6. Digestion of the DNA using endonucleases 
Restriction reaction was done following FastDigest (Thermo Fisher Scientific, USA) manual, 
using the necessary endonucleases.  
2.7. DNA ligation 
Gene ligation in the expression vector was done by following procedure: 
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Reaction mix: 
Fragment DNA (25-100 ng/µl) 1-3 µl; 
Expression vector DNA (25-100 ng/µl) 1-3 µl; 
10x T4 DNA Ligase buffer (Thermo Fisher Scientific, USA) - 2 µl; 
T4 DNA ligase (5 μ/µl) (Thermo Fisher Scientific, USA) - 1 µl; 
Water – up to 20 μl 
Ligation reaction was performed either for 1-2 h at room temperature, or overnight at +4° C. 
2.8. Plasmid transformation in E.coli 
Ligation mix (10-20 μl) was added to thawed competent cells and incubated for 10 min on 
ice. Heat shock was performed at 42° C for 35 seconds or two minutes depending on the cell type. 
After the heat shock cells were incubated on ice for two minutes. Afterwards 0.9 mL of LB medium 
(5 g/l Bacto yeast extract (Difco Laboratories), 10 g/l Bacto tryptone (Difco Laboratories), 10 g/l 
sodium chloride (Stanlab, Poland)) was added and cells were incubated for one hour at +37° C 
whilst slowly shaking the reaction mix. 100 μl of reaction mix was applied on LB agar plates (5 g/l 
Bacto yeast extract (Difco Laboratories), 10 g/l Bacto tryptone (Difco Laboratories), 10 g/l sodium 
chloride (Stanlab, Poland), 15 g/l Bacto agar (Difco Laboratories)) containing necessary antibiotic 
(kanamycin – 10 mg/mL or ampicillin - 20 mg/mL). Plates were incubated overnight at +37° C. 
2.9. E.coli cultivation for plasmid DNA amplification 
One colony from the Petri plates was transferred to 3 mL 2x TY (5 g/l Bacto yeast extract 
(Difco Laboratories), 16 g/l Bacto tryptone (Difco Laboratories), 5 g/l sodium chloride (Stanlab, 
Poland))  media containing necessary antibiotic (kanamycin – 10 mg/mL or ampicillin - 20 mg/ml) 
and incubated overnight at +37° C in a shaker (160-200 rpm) (Infors HT Multitron (Infors AG, 
Switzerland)). 
2.10. Plasmid purification from E.coli cells using GeneJET Plasmid Miniprep Kit. 
Plasmid DNA were isolated and purified using GeneJET Plasmid Miniprep Kit (Thermo 
Fisher Scientific, USA) following the user manual. 
2.11. DNA sequencing 
DNA sequencing was performed by following procedure: 
Reaction mix: 
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Big Dye (Applied Biosystems) – 1 μl; 
Big Dye 5x reaction buffer (Applied Biosystems) – 2 μl; 
Primer (1-5 pmol/µl). – 1 μl; 
Plasmid DNA (25-100 ng/µl)- 2 μl; 
Water – up to 20 μl 
PCR for sequencing was followed by standard protocol. 
 
DNA precipitation and washing were performed by the following procedure: 
Add 65 μl of 96% ethanol; 
Incubate 10-15 min at -20° C; 
Centrifugate 10-15 min, 13000 rpm using centrifuge 5418 R (Eppendorf, Germany); 
Remove the supernatant; 
Add 200 μl of 70% ethanol; 
Remove the supernatant; 
Centrifugate for 3 min, 13000 rpm using centrifuge 5418 R (Eppendorf, Germany); 
Remove the supernatant; 
Dry debris at 55° C; 
11 μl of formamide solution was added (Sigma, USA). Samples were heated for 5 min at 
+95° C, proceeding with immediate cooling on ice. Samples were analyzed using 3130xl Genetic 
analyzer (Applied Biosystems) and sequences were visualized using FinchTV (Geospiza, USA). 
2.12. E.coli cultivation for recombinant protein expression 
One colony from Petri plates was transferred to LB medium (5 g/l Bacto yeast extract (Difco 
Laboratories), 10 g/l Bacto tryptone (Difco Laboratories), 10 g/l sodium chloride (Stanlab, 
Poland)), containing necessary antibiotic (kanamycin – 10 mg/mL or ampicillin - 20 mg/ml) and 
proceeded without shaking at +37° C overnight. The prepared E.coli cultivation material was  
added to 2x TY (5 g/l Bacto yeast extract (Difco Laboratories), 16 g/l Bacto tryptone (Difco 
Laboratories), 5 g/l sodium chloride (Stanlab, Poland)) at maximum 1/10 ratio. Cells were 
incubated at +37° C, 160-200 rpm (Infors HT Multitron (Infors AG, Switzerland)) till OD540 
reached 0.6-0.8. Cells were induced with 0.2 mM IPTG (Thermo Fisher Scientific, USA) and 
grown for another 3-5 hours at +37° C, 160-200 rpm. Cell culture was harvested by centrifugation 
and stored frozen at -20° C. 
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2.13. Pichia pastoris cultivation for recombinant protein expression 
Linearized DNA containing the target gene was added to competent cells and incubated 15 
min in ice cold electroporation cuvette. Electroporation was done at 1.2 kV (Electroporator 2510, 
Eppendorf) immediately adding 1 mL YEPG medium (19 g/l peptone, 9.5 g/l yeast extract, 2 mL 
glucose) and incubating for 1 hour at 30° C. Cells were centrifugated at 8000 rpm (4° C), 
supernatant was removed and 1mL of distilled water was added to the cells. After resuspension, 
100 μl was spread on RDB plates (850 mL/l agar, 20 mL/l glucose, 3.4g/l yeast nitrogen base, 10g/l 
ammonium sulphate, 10 mL/l amino acid mix (L-methionine, L-glutamine, L-lysine, L-leucine, L-
isoleucine 5g/l), 0.4 mg/L biotin). First colonies appeared after 2-3 days of incubation at 30° C. To 
select for clones with multiple target gene integration , colonies from single plate were resuspended 
in 2-3 mL of YEP medium (20 g/l peptone, 10 g/l yeast extract), diluted 10x with distilled water 
and spread on YEPG agar plates (20 g/l peptone, 10 g/l yeast extract, 15 g/l agar, 20 mL/l glucose) 
containing 2-4 mg/ml geneticin. Plates were incubated for 2-5 days at 30° C and selected colonies 
were used for cultivation material preparation in YEPG medium with chloramphenicol (34 mg/l). 
The cultivation material was incubated for 3 days at 30° C without shaking.  
The prepared cultivation material was added to BMGY medium at 1:100 ratio (16 g/l 
peptone, 11.4 g/l yeast extract, 10 g/l ammonium sulphate, 100 mL/l potassium phosphate buffer 
pH 6.0 (2.3 g K2HPO4, 11.8 g KH2PO4), 10 mL glycerol) with 34 mg/l chloramphenicol and 
incubated at 30° C; 250 rpm until OD590 reached 6-8. 1% methanol was added every 24 hours for 
96 hours to induce protein synthesis. Cells were harvested by centrifugation and frozen until further 
use. 
2.14. Cell lysis using French press 
Cells were resuspended in lysis buffer solution (40 mM Tris 8.0, 200 mM NaCl, proceeding 
with three lysis cycles by French press at 20 000 psi using French Press cell disrupter (Thermo 
Electron, USA). Cell debris was removed by centrifugation for 60 min at 10 000 rpm, 4° C using 
centrifuge 5404 R (Eppendorf, Germany). 
2.15. Protein purification using metal affinity chromatography 
Lysed cell supernatant was purified using metal ion affinity Ni-NTA agarose columns 
(Thermo Fisher Scientific). Column was washed with cell lysis buffer solution, following wash 
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with lysis buffer containing 20 mM imidazole (AppliChem, Germany) and protein was eluted with 
lysis buffer containing 300 mM imidazole.  
2.16. His-tag cleavage using TEV protease 
TEV cleavage was performed for 1 hour at room temperature in 40mM Tris-HCl 8.0, 300 
mM NaCl, 300 mM imidazole, 1 mM DTT buffer. In-house produced TEV protease was used at 
ratio 25-50 μg per 1 mg of the target protein. 
2.17. Protein purification by gel filtration chromatography 
Proteins were purified using Superdex 200 10/ 300 GL column (GE Healthcare Life Sciences, 
Japan) linked to ÄKTA chromatography system (Amersham Biosciences, UK). Column was pre-
washed with 20 mM Tris-HCl 8.0, 200 mM NaCl. Flow rate was 1 mL/min, fraction size 1 mL. 
2.18. Protein purification by using ion-exchange chromatography 
For additional purification ion-exchange chromatography was performed - MonoQ TM 
column (GE Healthcare Life Sciences, Japan), salt gradient 0.1-0.5 M NaCl, flow rate 1 mL/min, 
fraction size 1 mL. 
2.19. SDS-PAGE electrophoresis 
Proteins were analyzed on SDS-PAGE electrophoresis by following procedure: 
Main gel (10 %): 
0.6 M Tris 8.8 (AppliChem, Germany)– 2 mL; 
Water – 4.5 mL; 
30 % acrylamide solution (Sigma, USA) – 3.3 mL; 
10% SDS (AppliChem, Germany) – 0.1 mL; 
10% ammonium persulfate (Sigma, USA) – 0.1 mL; 
TEMED (AppliChem, Germany) – 0.01 mL. 
After main gel is polymerized, upper layer of the gel (2%) is added: 
0.6 M Tris 6.8 (AppliChem, Germany) – 0.5 mL; 
Water – 3.75 mL; 
30 % acrylamide solution (Sigma, USA) – 0.7 mL; 
10 % SDS (AppliChem, Germany) – 0.05 mL; 
10 % ammonium persulfate (Sigma, USA) – 0.07 mL; 
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TEMED (AppliChem, Germany) – 0.007 mL. 
Samples were mixed with Laemmli sample loader (1% SDS (AppliChem, Germany), 40 mM 
Tris HCl pH 8.0, 0.05 % bromophenol blue (Merck, Germany), 2 % 2-Mercaptoethanol (Sigma, 
USA). 1x SDS running buffer (25 mM Tris (AppliChem, Germany), 192 mM glycine (AppliChem, 
Germany), 0.1% SDS (AppliChem, Germany)) was used and loaded samples were run on the SDS-
PAGE electrophoresis until the bromophenol blue stain reached the bottom of the gel. Gel was 
washed in 30% ethanol, 10% acetic acid solution for 20 min and proteins were stained using the 
Coomassie blue G-250 solution (Serva, Germany) for 20 minutes. Afterwards, washing with water 
was proceeded in order to wash away unbound stain.  
2.20. Protein desalting and concentration 
Proteins were desalted to 20 mM Tris-HCl, pH 8.0 buffer and concentrated to 10 mg/mL 
using 10k amicon ultra centrifugal filter (Merck Millipore Ltd, Ireland) at 4900 rpm, +4° C using 
centrifuge 5404 R (Eppendorf, Germany). 
2.21. Protein crystallization in complex with the ligands 
Crystallization was performed using TECAN crystallization robot (Evonik Industries, 
Switzerland) (0.4+0.4 μl drops) by co-crystallization, sitting drop, vapor diffusion method. 5-10 
mM inhibitor (final concentration, stock solution was prepared at 100 mM, dissolved in 100% 
DMSO (AppliChem, Germany)) was added to the protein solution before the crystallization.  
2.22. Diffraction data collection and structure determination 
Diffraction data were collected at MAX II and MAX IV (Lund, Sweden) or Bessy II (Berlin, 
Germany) synchrotrons. Images were indexed using MOSFLM (Leslie, 1992), scaled with SCALA 
(Evans, 1997) and molecular replacement was done using MOLREP (Vagin & Teplyakov, 1997). 
Ligand bond information was generated by LIBCHECK (Vagin et al., 1998). Ligand was manually 
fitted in the electron density using COOT (Emsley & Cowtan, 2004) followed by further REFMAC 
(Murshudov et al., 1997) runs. Structure was visualized using COOT (Emsley & Cowtan, 2004) 
and the PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
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3. Results 
3.1. 5-Substituted-(1,2,3-triazol-4-yl) thiophene-2-sulfonamides strongly inhibit 
human carbonic anhydrases I, II, IX and XII: Solution and X-ray crystallographic 
studies 
Various thiophene-sulfonamide derivatives were crystallized with hCA II in order to explain 
kinetic data displaying increase in selectivity for some of the hCA isoforms. In this work we 
published two of the determined crystal structures. Structure of hCA II in complex with compound 
with naphthyl moiety as a tail was determined at 1.35 Å resolution and with compound with phenyl 
cyano tail at 1.82 Å resolution. Both crystal structures displayed invariable orientation of 
sulfonamide group, interacting with Zn2+ ion and Thr199. Compound with naphthyl tail did not 
have any other polar interactions to stabilize ligand binding mode and ligand tail moiety orientation 
was achieved solely by hydrophobic and van der Waals contacts with residues Phe131, Val135, 
Pro202 and Leu204, fitting perfectly in the hydrophobic part of the enzyme active site. Comparing 
both structures, ligand binding differences can be noticed already starting from the thiophene ring, 
orientation of which in “cyano” and “naphthyl” structures differs by 180 degrees and the phenyl 
cyano tail is orientated towards the hydrophilic part of the enzyme active site pocket, while napthyl 
tail occupies the hydrophobic part. The compound with phenyl cyano tail also makes hydrogen 
bond with a highly conservative hCA residue Gln92, which according to the literature is a popular 
interaction (De Simone et al., 2013). Phenyl cyano tail also interacts with residues Val121, Phe131, 
Leu141, and Leu198. Due to the lack of cryoprotectant in the precipitant, 30% glycerol was added 
during flash freezing of crystals in liquid nitrogen. Apparently, the short soaking in cryoprotectant 
solution was long enough for a glycerol molecule to bind in the active site of hCA II in the same 
place as observed earlier for other hCA II structures (Avvaru et al., 2010). As glycerol is attached 
to the enzyme during cryoprotection it was assumed that it does not interfere with ligand binding 
and can be considered as an artifact. 
The obtained results suggest that the binding mode of compound can be directly influenced 
purely from hydrophobicity of the tail moiety. The results can be used for rational design of 
selective hCA II inhibitors, harboring both napthyl and phenyl cyano tails, able to bind both parts 
of the active site of enzyme.  
Crystal structures are deposited on PDB with access codes: 4BF1 and 4BF6. 
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3.2. X-ray crystallography-promoted drug design of carbonic anhydrase inhibitors 
It has been known previously that saccharin has properties of carbonic anhydrase inhibitor 
(Köhler et al., 2007). Saccharin proved to be much more selective to some of the mammalian CA 
isoforms than most of the medically used sulfonamide inhibitors. In later studies binding modes of 
saccharin-sulfonamide derivatives were tested. It was discovered that by addition of a sulfonamide 
group to the saccharine moiety it is energetically more favorable for the compound to bind to the 
Zn2+ ion via its sulfonamide moiety (Alterio et al., 2015b). Further saccharin-sulfonamide derivates 
were synthesized and three of them tested by crystallographic studies on hCA II. Atomic resolution 
crystal structures were achieved with clearly visible electron density for the ligand. The results 
were totally unpredicted – isothiazole cycle in the saccharin moiety was hydrolyzed and 
compounds were bound to the enzyme in a previously undescribed way. Unforeseen hCA II-ligand 
3D structures inspired synthesis of novel CA inhibitors – open ring saccharine derivatives.  
Further analysis of the compound suggested that all three of the tested compounds bind to 
the enzyme in a similar manner. Compounds formed hydrogen bonds with residues Asn67, Gln92 
and interacted with residues Phe131, Val135, Leu198, Pro202 and Leu204. 
This study is an example of how X-ray crystallography can promote drug design. All of the 
further saccharin-sulfonamide derivates were synthesized, inspired by these X-ray structures. 
Crystal structures are deposited on PDB with access codes: 5AMD, 5AMG and 5AML. 
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3.3. Efficient Expression and Crystallization System of Cancer-Associated Carbonic 
Anhydrase Isoform IX 
There is a limited number of semi-selective CA IX inhibitors described in literature. One of 
the reasons is the poor structural background of hCA IX-ligand interactions. Up until 2015 there 
was only one hCA IX crystal structure available in the PDB (Alterio et al., 2009). Limited number 
of available structural data for hCA IX can be explained by inefficient expression and purification 
systems. Also, the described crystallization conditions in literature could not be easily reproduced. 
We decided to develop hCA IX protein production and purification protocol suitable for X-
ray crystallography studies. hCA IX gene was genetically fused with MBP and N-terminal 6x His 
tag. Further, hCA IX gene was incorporated in Pichia pastoris by transfer plasmid vector. After 
selection of the most promising clones (in terms of protein production) the expression temperature 
was optimized to 24° C. Initially hCA IX-MBP was purified with a metal ion affinity column, 
followed by digestion with TEV protease. Additional purification using gel filtration column and 
ion exchange column was necessary to obtain 90+ % pure protein. Obtained hCA IX was 
crystallized using JCSG+ screen from Molecular Dimensions with following optimization. Three 
high resolution structures of hCA IX complexes with thiophene-2-sulfonamide derivatives were 
solved at resolutions ranging from 1.82 Å to 2.05 Å. Compounds were bound within the active site 
of hCA IX without additional polar contacts apart from the standard sulfonamide-Zn2+/Thr199 
interactions, meaning that the compound binding mode was stabilized solely by hydrophobic and 
van der Waals contacts. 
The observed electron density for all three compounds was good and interpretable throughout 
the whole ligand. Within the active site of hCA IX these compounds were bound in a similar way 
and their tail moieties were oriented towards the region which differs most between α-CA isoforms 
(“hot spot”) (Alterio et al., 2009). The compounds made interactions with residues Gln92, Val131, 
Leu135, Leu198, Thr200 and Pro202 (CA II numbering). 
Notable differences were observed comparing binding modes between hCA II and hCA IX. 
By analyzing the binding modes, we concluded that ligand tail moieties could not bind in the same 
way in hCA II as in hCA IX due to potential clash with Phe131 (CA II numbering).  
These results open wider possibilities for structure-based hCA IX targeted drug design in 
order to develop more selective compounds suitable for medical use.  
Crystal structures are deposited in PDB with access codes: 5FL4, 5FL5, 5FL6. 
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3.4. Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced 
acidification and clonogenic survival of cancer cells 
Using the previously described hCA IX expression, purification and crystallization system, 
multiple fluorinated benzene-sulfonamides were co-crystallized with the enzyme. Judging from the 
available kinetic data the tested sulfonamides had a remarkable increase in selectivity to hCA IX. 
The resolutions of obtained crystal structures were in a range from 1.75 Å to 2.47 Å with clearly 
interpretable electron densities for the ligands. The sulfonamide part and trifluorobenzene cycle 
part of the ligand fitted in the conservative region of hCA IX almost invariably compared to 
literature (Dudutiene et al., 2015). For all the tested compounds the cycloalkane moiety was 
oriented to the hydrophobic part of the enzyme active site while relatively more polar tail moiety 
with terminal hydroxyl group was oriented towards polar part of the hCA active site.  
The impressive selectivity against hCA II can be explained by occupation of the most diverse 
region of hCA by the bulky 12-carbon ring and potential collision with residue Phe131 in the case 
of compound VR16-09.  
Comparing to an un-liganded hCA IX structure, the determined crystal structures clearly 
displayed shifts in positions of conserved residues Gln67 and Gln92. This was the first time when 
it was observed that the ligand could interfere with the active site pocket conformation of hCA IX. 
Crystal structures are deposited on PDB with access codes: 6G98, 6G9U, 6FE0, 6FE1, 6FE2. 
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4. Discussion 
CAs are widespread in many life forms. There are at least 16 mammalian CA isoforms and 
some of them are associated with different diseases. In general – the enzymatic activities of various 
CA isoforms are favorable for various physiological processes, but in some cases, they promote 
development of various diseases (Supuran, 2012). The main focus of my thesis was on structural 
studies of ligand complexes with hCA II and hCA IX. hCA IX is considered to favor tumor cell 
proliferation (Chiche et al., 2009), while inhibition of hCA II lowers the intraocular pressure, thus 
relieving symptoms of glaucoma and lowering damage to the eye nerve (Mincione et al., 2008).  
All of the mammalian CAs display relatively high sequence identity but differ by localization in 
the cell and tissue and despite the same catalyzed reaction play different physiological roles. hCA 
isoforms display high sequence identity (23%-60%), and residues forming the active site pocket 
are even more conservative (Pinard et al., 2015). Only six residues out of 21 in the active site pocket 
are highly diverse between the isoforms thus making isoform selective inhibitor design a 
challenging task. Selective inhibition of an unwanted isoform is crucial to avoid disfunction of vital 
processes. Currently available medications, such as Diamox (acetazolamide), have poor selectivity 
and they target most of the CA isoforms with nanomolar affinity, thus displaying numerous side 
effects (Supuran, 2008b). Designing a molecule which fits the active site of CA enzyme so 
perfectly, that it has significantly lower affinity to all other isoforms is an ongoing research 
challenge.  
Available structural data of the protein – ligand interactions are essential for rational drug 
design. X-ray crystallography can give precise insight in ligand-enzyme complexes at atomic 
resolution. The obtained information notably increases the chance to design a compound targeted 
towards a specific isoform.   
At the beginning of my thesis work I crystallized hCA II in complex with five similar 
thiophene-2-sulfonamides. The thiophene-2-sulfonamides were designed based on available 
structural data of similar compounds - thiadiazole-2-sulfonamides. Acetazolamide is thiadiazole-
2-sulfonamide and it has been determined that acetazolamide with its thiadiazol moiety forms a 
hydrogen bond to highly conservative hCA active site residue Thr200. Since thiophene-2-
sulfonamide has no nitrogen atoms to form a hydrogen bond at that position we expected some 
difference in the ligand positioning due to weaker Van der Waals forces. Analysis of X-ray data 
showed that four of the compounds were bound very similarly within the active site of hCA II 
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interacting with the polar part, while compound with more hydrophobic tail moiety fitted in the 
hydrophobic part of hCA II. From the obtained results it could be concluded that orientation and 
binding mode of compound in the active site of enzyme can be directly affected solely by 
hydrophobicity of its tail moiety. Importantly, the obtained results can be used to generate an 
improved compound with combined binding properties of parent compounds – potential “dual tail” 
compounds possessing both polar and non-polar tails for potentially wider active site coverage and 
higher selectivity. 
Artificial sweetener saccharine was previously determined as a CA inhibitor by another research 
group with increase in selectivity comparing to sulfonamide class inhibitors (Köhler et al., 2007). 
It was previously determined that saccharine moiety with attached sulfonamide group prefers 
binding to the enzyme through its sulfonamide ZBG, as it is energetically more favorable (Alterio 
et al., 2015b). As newly synthesized compound tail moiety was attached to saccharine ZBG it was 
expected that compounds will bind to the Zn2+ ion through its sulfonamide group. The acquired 
crystal structures had atomic resolution and the attained electron density map clearly demonstrated 
an unexpected hydrolysis of the isothiazole cycle in the saccharine moiety.  Although hydrolysis 
of the isothiazole cycle most probably occurred due to the high pH level of the precipitant in the 
crystallization mix,  the binding mode of the compound allowed design of further CA-ligands with 
series of new open-ring saccharine derivatives with increase in selectivity to some of the CA 
isoforms (Ivanova et al., 2017). Although structural studies of hCA II are nothing unique, 
considering more than 775 structures available on the PDB, hCA II is still the most popular hCA 
isoform for studies of new ligand types due to easy experimental procedures. Even so, despite the 
massive structural data of hCA II, there is still no isoform specific inhibitor for hCA II and drug 
design for anti-glaucoma medicaments and diuretics is still an ongoing research field. 
One of the main targets for pharmacologically important enzyme drug design in the CA field 
is tumor associated hCA IX. The available data in literature suggests that enzymatic activity of 
hCA IX favors tumor growth and its inhibition could prevent cancer cell spread (Chen et al., 2005). 
Limited expression of hCA IX in normal tissues and overexpression in many tumors makes it a 
valid target for anti-cancer drug research (Mahalingam et al., 2018). A serious problem for design 
of an isoform specific hCA IX inhibitor was the lack of structural data about hCA IX – ligand 
interactions. Until 2015 there was only one hCA IX structure available in the PDB (Alterio et al., 
2009). Repeating crystallization conditions from the first published hCA IX catalytic domain 
structure failed and at that time the described expression method in baculovirus yielded very limited 
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quantity of protein. Therefore, we decided to develop a new protein expression and purification 
pathway suitable for structural studies. We managed to express a soluble and active hCA IX 
catalytic domain. Furthermore, we produced hCA IX crystals in complex with previously described 
thiophene-2-sulfonamides. Comparing binding modes of compounds among hCA II and hCA IX 
isoforms it was noted that all tested compounds were bound quite differently within the active sites 
of hCA IX and hCA II. By analyzing the binding modes, we concluded that all of the tested 
thiophene-2-sulfonamides were oriented to the part of the enzyme active site which differs most 
between all of the mammalian CA isoforms. Orientation differences of the tested thiophene-2-
sulfonamides can be explained by potential collision of the tail moiety with hCA II residue Phe131. 
Further research of thiophene-2-sulfonamide derivatives is ongoing targeting the most diverse hCA 
residues. 
Using our designed hCA IX catalytic domain expression, purification and crystallization 
system, multiple highly efficient fluorinated benzene-sulfonamides were co-crystallized with the 
enzyme. From the obtained data we solved several high resolution structures of ligand-hCA IX 
complexes of various nanomolar CA inhibitors.  The obtained structure of inhibitor VR16-09 in 
complex with hCA IX could explain the observed 1,000,000 fold selectivity of binding to hCA IX 
over hCA II. Being a good example of selective inhibitor design, VR16-09 made specific 
interactions in both polar and hydrophobic parts of the active site.  
By comparison of crystallographic and kinetic studies, it can be can concluded that the 8/12 
carbon ring at the ortho position results in a lower affinity towards many hCA isoforms whilst 
remaining a pico/nano molar inhibitor to hCA IX. The fluorobenzene cycle is positioned similarly 
in hCA IX-VR16-09, hCA IX-VR16-10 and hCA IX-VD12-09 crystal structures, despite 
differences in tail moieties. Fluorobenzene cycle fit in the conservative part of hCA IX and can be 
used for further inhibitor design. There are small differences regarding affinities to some hCA 
isoforms among the compounds VD12-09 and VR16-10, although they are structurally similar and 
differ only in polar tail moiety parts. The hydrophobic cycloalkane moiety and binding mode is 
identical within hCA IX of these compounds. Judging from X-ray data, the hydrophilic tail moieties 
of compounds VD12-09 and VR16-10 are oriented to the conservative part of hCA.  
If bound to hCA II, hydrophobic tails of VD12-09 and VR16-10 could potentially clash with 
one of the most diverse residues - Phe131. This provides higher selectivity against hCA II and 
many other hCA isoforms. 
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The cycloalkane group at meta- position results in much weaker selectivity against hCA II for 
compound VD11-4-2. The big eight carbon cycle at meta- position does not affect the positioning 
of the hydrophobic ring but has an overall effect on fluorobenzene cycle orientation. Another 
difference between VD11-4-2 and other compounds is the fact that the there is -SO2- group instead 
of -S- at the para- tail which results in two additional hydrogen bonds with residues Asn62 and 
Gln92. Sulfonyl part of the VD11-4-2 hydrophilic tail moiety linker perfectly fits between two 
polar residues occupying that part of the hCA IX active site thus potentially providing further clue 
for rational design of polar tail of similar derivatives. 
 In conclusion, my work has provided several clues for isoform-specific inhibitor design of hCAs. 
The most important part of the performed study was creation of efficient hCA IX production, 
purification and crystallization system, which was successfully used for further structural and 
kinetic studies. 
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5. Conclusions 
1. Thiophene-2-sulfonamides are effective human carbonic anhydrase inhibitors, with 
tail moiety orientation towards the hot spot for isoform selective drug design. 
2. Ligand orientation within the active site of carbonic anhydrases can be affected solely 
by hydrophobicity of tail moiety. 
3. Isothiazole cycle in saccharin moiety can be hydrolyzed in high pH environment 
forming open ring saccharine derivatives which work as semi-selective CA inhibitors. 
4. Genetic fusion of catalytic domain of hCA IX with MBP in combination with 
expression in Pichia pastoris results in high yields of soluble and enzymatically 
active enzyme. 
5. Fluorinated benzene-sulfonamides with cycloalkane moiety at the ortho position are 
nanomolar hCA IX inhibitors with notable increase in selectivity, comparing to 
widely used carbonic anhydrase inhibitors. 
6. Fluorinated benzene-sulfonamides can alter enzyme active site pocket conformation 
by changing the side chain rotamers to their favorable orientation.  
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6. Main thesis for defense 
1. Thiophene-2-sulfonamides can be used for targeting the most diverse region of hCA 
active site.  
2. Open form 1-N-substituted saccharins are highly efficient hCA II inhibitors. 
3. Expression system in Pichia pastoris is suitable for production of hCA IX catalytic 
domain in high amounts. 
4. Increase in selectivity for fluorinated benzene-sulfonamides with cycloalkane tail 
moiety at ortho- position interacts with the most diverse hCA residues thus providing 
a promising anti-cancer drug candidate. 
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